Carbazole scaffolds in cancer therapy: a review from 2012 to 2018

Journal of Enzyme Inhibition and Medicinal Chemistry

Samar Issa¹  Pål Rongved²  Saïd Yous³  Nicolas Bedel⁴  Marc Le Borgne⁴  Zouhair Bouaziz⁴  Anthony Prandina⁴ 

[1] Ecole de Biologie Industrielle, EBInnov;School of Pharmacy, University of Oslo;Université Lille, Inserm, CHU Lille, UMR-S 1172 JPArc Centre de Recherche Jean-Pierre Aubert Neurosciences et Cancer;Université de Lyon, Université Claude Bernard Lyon 1;

关键词: carbazole;    cancer;    cytotoxicity;    targeted therapy;    enzyme inhibitors;   

DOI  :  10.1080/14756366.2019.1640692

来源: DOAJ

【 摘 要 】

For over half a century, the carbazole skeleton has been the key structural motif of many biologically active compounds including natural and synthetic products. Carbazoles have taken an important part in all the existing anti-cancer drugs because of their discovery from a large variety of organisms, including bacteria, fungi, plants, and animals. In this article, we specifically explored the literature from 2012 to 2018 on the anti-tumour activities reported to carbazole derivatives and we have critically collected the most significant data. The most described carbazole anti-tumour agents were classified according to their structure, starting from the tricyclic–carbazole motif to fused tetra-, penta-, hexa- and heptacyclic carbazoles. To date, three derivatives are available on the market and approved in cancer therapy.

【 授权许可】

Unknown